Depressive DisordersPTSDSubstance Use Disorders (SUD)Immunology & InflammationKetaminePsilocybinLSD

Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms

This review (2021) presents the neurobiological therapeutic mechanisms by which psychedelics work, with a focus on outcomes on 1) neuroplasticity, 2) immune system, and 3) effects on neurotransmitter (-modulator) systems.

Authors

  • Danilo De Gregorio
  • Gabriella Gobbi

Published

Pharmacological Reviews
meta Study

Abstract

Mounting evidence suggests safety and efficacy of psychedelic compounds as potential novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug Administration in a new class of antidepressants, and 3,4-methylenedioxymethamphetamine (MDMA) is undergoing phase III clinical trials for post-traumatic stress disorder. Psilocybin and lysergic acid diethylamide (LSD) are being investigated in several phase II and phase I clinical trials. Hence, the concept of psychedelics as therapeutics may be incorporated into modern society. Here, we discuss the main known neurobiological therapeutic mechanisms of psychedelics, which are thought to be mediated by the effects of these compounds on the serotonergic (via 5-HT2A and 5-HT1A receptors) and glutamatergic [via N-methyl-d-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors] systems. We focus on 1) neuroplasticity mediated by the modulation of mammalian target of rapamycin-, brain-derived neurotrophic factor-, and early growth response-related pathways; 2) immunomodulation via effects on the hypothalamic-pituitary-adrenal axis, nuclear factor ĸB, and cytokines such as tumour necrosis factor-α and interleukin 1, 6, and 10 production and release; and 3) modulation of serotonergic, dopaminergic, glutamatergic, GABAergic, and norepinephrinergic receptors, transporters, and turnover systems. We discuss arising concerns and ways to assess potential neurobiological changes, dependence, and immunosuppression. Although larger cohorts are required to corroborate preliminary findings, the results obtained so far are promising and represent a critical opportunity for improvement of pharmacotherapies in psychiatry, an area that has seen limited therapeutic advancement in the last 20 years. Studies are underway that are trying to decouple the psychedelic effects from the therapeutic effects of these compounds.

Available with Blossom Pro

Research Summary of 'Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms'

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

Cited By (45)

Papers in Blossom that reference this study

An open-label pilot study of psilocybin-assisted therapy for binge eating disorder

Dallery, J., Miller, J. L., Boissoneault, J. et al. · Journal of Eating Disorders (2026)

DMT-induced shifts in criticality correlate with self-dissolution

Irrmischer, M., Aqil, M., Luan, L. et al. · Journal of Neuroscience (2025)

Psilocybin’s effect on human brain synaptic plasticity

Johansen, A., Plavén-Sigray, P., Madsen, M. K. et al. · Research Square (2025)

The psychoplastogen tabernanthalog induces neuroplasticity without proximate immediate early gene activation

Aarrestad, I. K., Cameron, L. P., Fenton, E. M. et al. · Nature Neuroscience (2025)

Low-Dose LSD Alters Early and Late Event-Related Potentials to Emotional Faces

Haggarty, C. J., Molla, H. M., Glazer, J. et al. · Psychedelic Medicine (2024)

2 cited
The Impact of Antidepressant Discontinuation Prior to Treatment with Psilocybin for Treatment-Resistant Depression

Marwood, L., Croal, M., Mistry, S. et al. · Journal of Psychiatric Research (2024)

Show all 45 papers
Childhood trauma, challenging experiences, and posttraumatic growth in ayahuasca use

Cassidy, K., Healy, C. J., Henje, E. et al. · Drug Science Policy and Law (2024)

Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential

Allen, J., Dames, S., Foldi, C. J. et al. · Molecular Psychiatry (2024)

Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics

Jaster, A. M., González-Maeso, J. · Molecular Psychiatry (2023)

Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD

Kovacevich, A., Weleff, J., Claytor, B. et al. · Journal of Psychoactive Drugs (2023)

5 cited
The potential of psychedelics for the treatment of Alzheimer's disease and related dementias

Winkelman, M. J., Szabo, A., Frecska, E. · European Neuropsychopharmacology (2023)

Spatial correspondence of LSD-induced variations of brain functioning at rest with serotonin receptor expression

Pizzi, S. D., Chiacchiaretta, P., Sestieri, C. et al. · Biological Psychiatry (2023)

A non-hallucinogenic LSD analog with therapeutic potential for mood disorders

Lewis, V., Bonniwell, E. M., Lanham, J. K. et al. · Cell Reports (2023)

102 cited
Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation

Burmester, D., Madsen, M. K., Szabo, A. et al. · Comprehensive Psychoneuroendocrinology (2023)

5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines

Cameron, L. P., Patel, S. D., Vargas, M. V. et al. · ACS Chemical Neuroscience (2023)

86 cited
Default Mode Network Modulation by Psychedelics: A Systematic Review

Gattuso, J. J., Perkins, D., Ruffell, S. G. D. et al. · International Journal of Neuropsychopharmacology (2022)

Towards an understanding of psychedelic-induced neuroplasticity

Calder, A. E., Hasler, G. · Neuropsychopharmacology (2022)

A long trip into the universe: Psychedelics and space travel

Lerer, L. B., Varia, J. · Frontiers in Space Travel (2022)

2 cited
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution

Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)

7 cited
LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility

Wießner, I., Olivieri, R., Falchi, M. et al. · European Neuropsychopharmacology (2022)

Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder

Markopoulos, A., Inserra, A., De Gregorio, D. et al. · Frontiers in Pharmacology (2022)

30 cited
Classic Psychedelic Drugs: Update on Biological Mechanisms

Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)

71 cited
Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective

Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)

Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder

Doss, M. K., Považan, M., Rosenberg, M. D. et al. · Translational Psychiatry (2021)

249 cited
Serotonergic Psychedelics in Neural Plasticity

Torregrossa, M. M., Lu, J., Lukasiewicz, K. et al. · Frontiers in Molecular Neuroscience (2021)

Psychedelics, sociality, and human evolution

Rodríguez Arce, J. M., Winkelman, M. J. · Frontiers in Psychology (2021)

Psychedelic perceptions: mental health service user attitudes to psilocybin therapy

Corrigan, K., Haran, M., Mccandliss, C. et al. · Irish Journal of Medical Science (2021)

Catalysts for change: the cellular neurobiology of psychedelics

Bement, W., Banks, M. I., Zahid, Z. et al. · Molecular Biology of the Cell (2021)

31 cited
On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review

Zeifman, R. J., Singhal, N., Breslow, L. et al. · ACS Pharmacology and Translational Science (2021)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

Psychedelics in Psychiatry: Neuroplastic,... — Research Summary & Context | Blossom